Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Combining xanomeline and trospium, Cobenfy selectively targets M1 and M4 receptors, rather than traditional dopamine ... Ebglyss (lebrikizumab) developed by Eli Lilly and Co and Almirall|atopic ...

Eli Lilly and Company (NYSE ... a refreshed low-cost iPad, and an M4 MacBook Air. The iPhone SE, the company’s first device with an Apple 5G modem, will see an update in 2025, and it is expected ...

Also covered by the pact is a dual M1/M4 agonist and a selective M1 agonist ... originally developed by Eli Lilly, that had been shelved because it was hard to tolerate. Karuna's solution is ...

ALIA-1758 is in the same general class as Eisai/Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab ... Finally, it is testing muscarinic M4 receptor-targeting candidate emraclidine ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Reports Q4 revenue $13.53B, consensus $13.43B. “2024 was a highly successful year for Lilly,” said David Ricks, Lilly’s chair and CEO. “We had ...

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The ...

EST: Adds comments from Seeking Alpha analyst BioCGT Investor Eli Lilly (NYSE:LLY) on Thursday reported its Q4 2024 results, exceeding Wall Street forecasts and indicating a more than twofold rise in ...